A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies

What is the purpose of this trial?

This study is to determine first, the recommended Phase 2 dose of NKTR-214 when administered in combination with nivolumab, and then, the clinical benefit, safety, and tolerability of combining NKTR-214 with nivolumab in select patients with melanoma, renal cell carcinoma or non-small cell lung cancer. Both drugs target the immune system and may act synergistically to promote anti-cancer effects.



Nektar Therapeutics

Start Date: 05/09/2017

End Date: 06/30/2020

Last Updated: 02/14/2019

Study HIC#: 1609018350

Get Involved

For more information about this study, contact:
Neta Shanwetter Levit
+1 203-737-6247
neta.shanwetterlevit@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image